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Recently, a Surveillance Epidemiology and End Results (SEER) survey of melanoma patterns of care by the Mayo
Clinic, Scottsdale showed remarkable deviations from best practice patterns throughout the country. The study,
which analyzed the SEER records of 35,126 stage I to III cutaneous malignant melanoma patients treated from 2004
to 2006, showed that adherence to National Comprehensive Cancer Network (NCCN) therapeutic resection margins
occurred in less than 36% of patients. Similarly, considerable variation in the quality of melanoma care in the
United States when assessed using 26 quality indicators drawn by a panel of melanoma experts was
independently reported. These observations underscore the significant lack of adherence to published best practice
patterns reflected by the NCCN guidelines. The untoward effects of these variations in practice pattern can have an
inordinate impact on the survival of melanoma patients in whom long term outcomes are affected by the
adequacy of surgical management. Thin malignant melanoma is curable; however, thick or node positive
melanoma is often incurable. This outcome is determined not only by the stage at presentation but by the use of
best practice patterns as reflected in current NCCN cutaneous melanoma practice guidelines.
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Review
Recently, a Surveillance Epidemiology and End Results
(SEER) survey of melanoma patterns of care by the Mayo
Clinic, Scottsdale showed remarkable deviations from best
practice patterns throughout the country. The study,
which analyzed the SEER records of 35,126 stage I to III
melanoma patients treated from 2004 to 2006, showed
that adherence to National Comprehensive Cancer Net-
work (NCCN) therapeutic resection margins occurred in
less than 36% of patients [1]. In as many as 11% of patients
the initial diagnostic excisional biopsy was the only surgi-
cal resection undertaken. Approximately 40% of these
patients were eligible for sentinel node biopsy (SNB) based
on their micro-staging. However, only 53% of these
patients ever had the SNB performed. Among those
whose SNB was positive, 27% never had a therapeutic
completion node dissection (CLND). These observations
underscore the significant lack of adherence to published
best practice patterns reflected by the NCCN guidelines.
These guidelines are widely available on-line and remain
the standard of care. Why is it that they are not universally
utilized?
The departure from NCCN standards could be ascribed
to the fact that most melanoma patients are not treated by
trained melanoma specialists. Cursory review of the lengthy
and thorough NCCN guidelines by episodic melanoma
practitioners may be part of the problem. This was sug-
gested by a recent publication by Erickson et al. (2008) in
the community hospital setting where they observed that
compliance with NCCN melanoma guidelines was subopti-
mal among non-surgical oncologists when compared to
surgical oncologists [2]. In an attempt to formulate the
NCCN standards into measurable quality indicators, Bili-
moria (2009) reported that there remains “considerable
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variation in the quality of melanoma care in the United
States” when assessed using 26 quality indicators drawn by
a panel of melanoma experts [3]. For example, they report
that only 25% of stage IB or II melanoma patients treated at
Veteran Administration Hospitals in the United States had
SNB compared to 60% at NCCN hospitals or 43% in the
community hospital setting. Interestingly, most of the
deviation in best practice patterns reported above result
from the underutilization of a small subset of these guide-
lines [4]. However, it is noteworthy that non-adherence to
this small subset of the guidelines results in the greatest
deleterious impact on patient outcomes. Conversely, heigh-
tened attention to this subset may lead to significant
improvement in clinical outcomes. More importantly, this
primer should encourage even the inveterate practitioner to
review the complete set of guidelines before embarking on
the final treatment decision.
We propose to focus on the indispensable essentials,
which account for the observed departure from adher-
ence to the current NCCN standards for the surgical
management of malignant melanoma. This selective
approach could lead to decreased variation in the
observed national practice patterns and improve out-
comes. We fully underscore the importance of all of the
NCCN guidelines but also recognize that the contempor-
ary data suggests that they are not widely adopted. This
adjunct to best practice patterns is amenable for use in
academic and non-academic centers alike. This subset of
the NCCN guidelines addresses the primary elements of
melanoma diagnosis and treatment, which although
notably deficient in the reported national studies, is
employed by trained surgical and medical oncologists
expert in the field. Focusing our attention on these
streamlined guidelines may avert departures from NCCN
best practice patterns. They address the following essen-
tial elements:
1) Diagnosis and biopsy
2) Microstaging and metastatic staging work up
3) Therapeutic resection margins
4) Indications for nodal staging with SNB
5) Therapeutic CLND
6) The role of metastasectomy in melanoma
management
Diagnosis and biopsy
All pigmented cutaneous lesions, in which melanoma is
included in the clinical differential diagnosis, should
undergo a complete full thickness excisional biopsy with
minimal margins. For convenience, this can be done easily
with a punch biopsy, which should include adjacent nor-
mal appearing skin [5]. Shave biopsy should be discour-
aged as superficial shaves may under stage the actual
thickness or micro-staging of a lesion and confound
subsequent treatment decisions, which are based solely on
thickness, ulceration and mitotic activity. Melanoma can
be fatal; therefore, all cutaneous lesions, which include
melanoma as a possible diagnosis, should be biopsied.
Micro-staging and metastatic staging work up
Although increasing annually in incidence, the majority of
melanoma patients present with stage I disease. Only 16%
of melanoma patients have nodal metastasis at diagnosis;
therefore, for lesions with minimal likelihood of nodal
metastasis no metastatic work up is indicated [6]. Patients
with node negative thin (< 1 mm) melanoma and inter-
mediate thickness melanoma (1 to 4 mm) without nodal
involvement or specific symptoms suggestive of metastatic
disease need not undergo a metastatic work up, computed
tomography (CT) or CT/positron emission tomography
(PET) or brain CT. In these patients (Stage IIa), the yield
of positive findings on imaging is very low and those
found to have a positive sentinel node could undergo
metastatic work up after the SNB discloses the need for
such a work-up prior to therapeutic CLND (Coit, 2011)
[7]. Intermediate thickness melanoma with high risk fea-
tures (ulceration, increased mitotic activity defined as
greater than one mitotic figure per high power field) on
micro-staging should likely undergo a metastatic work-up
prior to SNB. No specific data exist to break down this
recommendation by thickness; therefore, the decision is
up to the treating physician. Likewise, thick melanoma
(> 4 mm) is accompanied by substantial risk (> 60%) of
distant metastases and should undergo a preoperative
metastatic work-up. In the age of PET/CT, dedicated CT
or magnetic resonance imaging (MRI) can be used to
define inconclusive PET/CT findings, such as liver or
brain involvement or elevated lactate dehydrogenase
LDH.
Therapeutic resection margins
Often the pathologist’s report of a diagnostic biopsy of
melanoma will include a statement regarding the pre-
sence or absence of tumor at the biopsy margins. This
information is of no significance and can mislead many
primary care physicians into not seeking additional sur-
gical consultation. Therapeutic margins for melanoma
are a function of the micro-staging thickness of the mel-
anoma. Clear radial margins of 1 cm are required for all
thin melanoma while 2 cm radial margins are recom-
mended for all intermediate thickness lesions. These evi-
dence-based recommendations have been designed to
avoid a local recurrence, which is accompanied by a dis-
mal five-year survival. Thick melanoma can be managed
with 2 cm radial margins or greater if the lesion is asso-
ciated with clinically evident satellitosis [7]. Melanoma
in situ which has no metastatic potential should be
excised with a 5 mm radial margin designed to remove
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all of the pre-malignant tissue to avoid a potential local
invasive recurrence.
Indications for nodal staging with SNB
Indications for nodal staging with SNB [8] in patients
whose performance status is permissive of a subsequent
therapeutic lymphadenectomy are:
A) All high risk thin melanoma (< 1 mm thick but
associated with ulceration, increased mitotic activity
or Clark level IV or V) should undergo SNB.
B) All melanoma thicker than 1 mm should undergo
SNB.
Therapeutic CLND
Unlike breast cancer, where contemporary evidence [9]
has determined that lymphadenectomy for breast cancer is
foremost a staging procedure, lymphadenectomy for cuta-
neous malignant melanoma is currently regarded as a
therapeutic procedure. Morton has elegantly showed that
all sentinel node micro-metastases progress to clinical
macro-metastases [10]. Therefore, lymph node manage-
ment for melanoma is different than that for breast cancer,
a more familiar condition to many practicing physicians.
All patients with good performance status who have
positive sentinel nodes should undergo a therapeutic
CLND. Surgeons experienced in more complicated proce-
dures, such as radical groin dissections or modified neck
dissections, may be consulted in this setting. The presence
of non-sentinel node involvement documented only by
CLND is a significant adverse prognostic indicator. In a
study by Coit et al., 2,009 patients with positive non-senti-
nel node involvement had a median survival of 33 months
while those with no non-sentinel node involvement had a
median survival of 104 months [11]. These findings affirm
the need for CLND in patients with a positive SNB. Yet, as
reported by Wasif, 2010, Erickson, 2008 and more expli-
citly by McMasters, 2010, many have reported that only
50 to 69% of melanoma patients in the USA undergo a
therapeutic CLND for positive SNB. In a preliminary
review, among patients with histological positive SNB, the
Multi-Center Lymph Node Trial demonstrated that
patients undergoing a CLND showed a five-year survival
advantage over those who did not (72.3% vs. 52%) [10,12].
In the Sunbelt Melanoma Trial, patients completing a
CLND for positive SNB had a 67% five-year survival.
Lastly, CLND affords excellent loco-regional control with
nodal recurrence rates less than 4% compared with those
not subject to a CLND for positive SNB [6]. In short,
patients with pathologic stage III disease can be rendered
free of tumor with aggressive loco-regional surgical ther-
apy leading to improved survival.
The role of metastasectomy in melanoma management
Recent progress in the targeted systemic therapy of stage
IV melanoma is admittedly modest [13]. Thus, selective
surgical intervention remains the mainstay for eradica-
tion of loco-regional recurrence at favorable metastatic
sites. The success of aggressive metastasectomy hinges
on the understanding of the biological behavior of mela-
noma and specifically the course of the illness on the
individual patient. Without question, a long disease-free
interval in excess of three to five years or more is a very
important criterion for considering resection of a solitary
metastatic focus. Solitary recurrences of the soft tissue
and lung can be resected with excellent long term out-
come. More modest outcomes can be seen in the resec-
tion of single brain metastasis and in selected patients
even surgical intervention for liver metastases is useful
[14,15].
In transit metastases defined as soft tissue, skin or
dermal recurrences between the primary site and its
anatomic nodal drainage basin are a frequent site of
loco-regional recurrence. These are usually too numer-
ous to resect, particularly when found in the extremities.
In the extremities these are often expected sequelae in
patients with thick melanoma with microscopic satellito-
sis and positive sentinel nodes who undergo a CLND.
Prospective studies [16] from the Sidney Melanoma
Unit in Australia have shown that isolated heated limb
infusion as described by Thompson results in remark-
able response rates in 85 to 95% of patients and eradica-
tion of disease defined as a complete remission in 50%.
The technique is reproducible but calls for collaboration
between surgeons, surgical oncologists, perfusionists and
interventional radiologist for optimal outcomes.
In summary, even in the metastatic setting aggressive
surgical management of selected stage IV patients can
be very effective [14].
Conclusions
Increased attention to the essential elements of current
NCCN management guidelines for the surgical treatment
of patients with cutaneous malignant melanoma can
improve the care of most of these patients who present
with early disease and improve outcomes. Variations in
practice patterns resulting from the disuse of this subset of
the guidelines account for most of the reported departure
from best practice patterns. Additional recommendations
to curb these practice variations, such as the inclusion of
all melanoma patients in discussions at multi-disciplinary
tumor boards, should already be in place. Yet, the sheer
numbers of patients with early or favorable presentation
does not permit the review of all of these cases, even in
academic specialty centers. Another option is regionaliza-
tion of care for malignant melanoma as has been done for
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complicated tumors, such as pancreatic or esophageal can-
cers. However, 1 in 74 Americans is diagnosed with cuta-
neous melanoma [17] and in the majority their
management does not incur the potential morbidity and
mortality inherent to the surgical management of pancrea-
tic or esophageal cancer patients, which has resulted in
the regionalization of their care. Therefore, regionalization
would probably be impractical and costly.
The data suggest that the management of the newly
diagnosed patient with malignant melanoma remains
primarily a community-based surgical problem. An
understating of the natural course of the illness and the
role of surgical intervention in arresting its progression
remains the most important determinant of satisfactory
long term outcomes. In that vein, adherence to best
practice patterns as elucidated by the NCCN standards
should be paramount. Currently, reported variations in
adherence to these best practice patterns in the surgical
management of malignant melanoma can only have a
negative impact on the overall survival of these patients.
Yet, as shown herein, renewed attention to a key subset
of admittedly underused NCCN guidelines for mela-
noma could lead to a significant improvement in out-
comes. Approaches such as those suggested here may
also enhance the use of the entire set of guidelines and
narrow the reported variability in practice patterns.
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